As 2022 proves to be a year of missed predictions and uncertainty, we are using this year's BIO notebook to provide additional context by reviewing different industry metrics to provide more perspective to the comments coming from the meeting.
Biotechnology stock valuations are down 30%-50% over the past year, depending on which index you track, impacting the ability of...








